By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Avant Immunotherapeutics 

Name change to Celldex Therapeutics
Press releases archived for reference only.
Needham  Massachusetts    U.S.A.
Phone: n/a Fax: n/a



Company News
Avant Immunotherapeutics Announces Name Change to Celldex Therapeutics, Inc.; Anthony S. Marucci Appointed President and CEO 9/29/2008 8:48:04 AM
Avant Immunotherapeutics (AVAN) CEO To Present at the UBS Warburg 2008 Global Life Sciences Conference September 23 9/19/2008 9:42:49 AM
Avant Immunotherapeutics (AVAN) CEO to Present at the 28th Annual Canaccord Adams Global Growth Conference 8/9/2008 11:25:40 PM
Avant Immunotherapeutics (AVAN) to Report Second Quarter 2008 Financial Results on August 6, 2008 8/4/2008 12:53:35 PM
3M Drug Delivery Systems Collaborates with Avant Immunotherapeutics (AVAN) on Vaccine Adjuvants 6/11/2008 9:00:42 AM
Avant Immunotherapeutics (AVAN) CEO to Present at the Needham & Company Biotechnology & Medical Technology Conference 6/4/2008 10:01:23 AM
National Institutes of Health (NIH) Initiates Phase 1 Safety Study of Avant Immunotherapeutics (AVAN)'s Oral Combined Enterotoxigenic E. coli-Cholera Vaccine 6/4/2008 8:44:28 AM
Avant Immunotherapeutics (AVAN) Data Shows Brain Cancer Vaccine Doubles Survival 6/3/2008 6:15:36 AM
Avant Immunotherapeutics (AVAN) Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 5/22/2008 1:29:49 PM
Avant Immunotherapeutics (AVAN) Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer Inc. (PFE) 5/21/2008 7:45:57 AM